MedTrace Logo

Treatment With Erythropoietin and Cognition During Hypoglycaemia

NCT00615368 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2015-08-24

No results posted yet for this study

Summary

The purpose of the trial is to determine if erythropoietin (EPO) can enhance cognitive function during hypoglycaemia in patients with type 1 diabetes.

Patients with type 1 diabetes will receive one injection of EPO. Hypoglycaemia will be induced 6 days after. Before (1 hour), during and after (1 hour) hypoglycaemia, the cognitive function will be measured.

Conditions

Interventions

DRUG

Epoetin alfa

1 (one) intravenously injection of 40.000 IU epoetin alfa 6 days before induction of experimental hypoglycemia.

DRUG

Isotonic NaCl (Placebo)

1 ml. of isotonic NaCl is intravenously injected 6 days before induction of experimental hypoglycaemia

Sponsors & Collaborators

  • Maastricht University Medical Center

    collaborator OTHER

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Steno Diabetes Center Copenhagen

    collaborator OTHER

  • Erasmus Medical Center

    collaborator OTHER

  • Aarhus University Hospital

    collaborator OTHER

  • Hillerod Hospital, Denmark

    lead OTHER

Principal Investigators

  • Peter L Kristensen, MD · Hillerod Hospital, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-12-31
Completion
2010-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00615368 on ClinicalTrials.gov